Why the study?
Morphine analgesia may reduce the absorption of co-prescribed P2Y12 antagonists and attenuate platelet inhibition, but the clinical impact of periprocedural intravenous morphine during primary PCI for STEMI is not well defined.
Does periprocedural intravenous morphine affect in-hospital or 30-day MI and mortality in patients undergoing primary PCI for STEMI?
Population
Patients undergoing primary PCI for STEMI across 11 studies
Comparison
Periprocedural intravenous morphine vs no periprocedural intravenous morphine
Design
Systematic review and meta-analysis of 1 RCT and 10 observational studies
Follow-up
In-hospital or 30-day
Authors
Loading...
Reassures on morphine safety for STEMI PCI analgesia; confirms neutral short-term MI and mortality association in meta-analysis.
Does periprocedural intravenous morphine affect in-hospital or 30-day MI and mortality in patients undergoing primary PCI for STEMI?
Periprocedural intravenous morphine administration during primary PCI for STEMI is not associated with an increased risk of short-term adverse clinical outcomes such as MI or mortality.
Batchelor et al. (2019) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: